| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Department of Immunology and Bacteriology, Western Infirmary, and
Center for Rheumatic Diseases, Royal Infirmary, Glasgow, United Kingdom;
Pharming Technologies, Leiden, The Netherlands; and
Instituto Finlay, Havana, Cuba
Lactoferrin (Lf) is an iron-binding protein of external secretions
and neutrophil secondary granules with antimicrobial and
immunomodulatory activities. To further define these properties of Lf,
we have investigated the response to Staphylococcus
aureus infection in transgenic mice carrying a functional human
Lf gene. The transgenic mice cleared bacteria
significantly better than congenic littermates, associated with a trend
to reduced incidence of arthritis, septicemia, and mortality. We
identified two pathways by which S. aureus clearance was
enhanced. First, human Lf directly inhibited the growth of S.
aureus LS-1 in vitro. Second, S. aureus-infected
transgenic mice exhibited enhanced Th1 immune polarization. Thus,
spleen cells from infected transgenic mice produced higher levels of
TNF-
and IFN-
and less IL-5 and IL-10 upon stimulation ex vivo
with the exotoxin toxic shock syndrome toxin-1 compared with
congenic controls. To confirm that these effects of Lf transgene
expression could occur in the absence of live bacterial infection, we
also showed that Lf-transgenic DBA/1 mice exhibited enhanced severity
of collagen-induced arthritis, an established model of Th1-induced
articular inflammation. Higher levels of stainable iron in the spleens
of transgenic mice correlated with human Lf distribution, but all other
parameters of iron metabolism did not differ between transgenic mice
and wild-type littermates. These results demonstrate that human Lf can
mediate both antimicrobial and immunomodulatory activities with
downstream effects on the outcome of immune pathology in infectious and
inflammatory disease.
This article has been cited by other articles:
|
|
 |
|
  N. J. Jann, M. Schmaler, S. A. Kristian, K. A. Radek, R. L. Gallo, V. Nizet, A. Peschel, and R. Landmann Neutrophil antimicrobial defense against Staphylococcus aureus is mediated by phagolysosomal but not extracellular trap-associated cathelicidin J. Leukoc. Biol., November 1, 2009; 86(5): 1159 - 1169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Spadaro, C. Caorsi, P. Ceruti, A. Varadhachary, G. Forni, F. Pericle, and M. Giovarelli Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells FASEB J, August 1, 2008; 22(8): 2747 - 2757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Clarke and S. J. Foster IsdA Protects Staphylococcus aureus against the Bactericidal Protease Activity of Apolactoferrin Infect. Immun., April 1, 2008; 76(4): 1518 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Spadaro, C. Curcio, A. Varadhachary, F. Cavallo, J. Engelmayer, P. Blezinger, F. Pericle, and G. Forni Requirement for IFN-{gamma}, CD8+ T Lymphocytes, and NKT Cells in Talactoferrin-Induced Inhibition of neu+ Tumors Cancer Res., July 1, 2007; 67(13): 6425 - 6432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Wolf, G. Li, A. Varadhachary, K. Petrak, M. Schneyer, D. Li, J. Ongkasuwan, X. Zhang, R. J. Taylor, S. E. Strome, et al. Oral Lactoferrin Results in T Cell-Dependent Tumor Inhibition of Head and Neck Squamous Cell Carcinoma In vivo Clin. Cancer Res., March 1, 2007; 13(5): 1601 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-J. Li, M.-C. Lu, S.-C. Hsieh, C.-H. Wu, H.-S. Yu, C.-Y. Tsai, and C.-L. Yu Release of surface-expressed lactoferrin from polymorphonuclear neutrophils after contact with CD4+T cells and its modulation on Th1/Th2 cytokine production J. Leukoc. Biol., August 1, 2006; 80(2): 350 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Naot, A. Grey, I. R Reid, and J. Cornish Lactoferrin - A Novel Bone Growth Factor Clin. Med. Res., May 1, 2005; 3(2): 93 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Dijkshoorn, C. P. J. M. Brouwer, S. J. P. Bogaards, A. Nemec, P. J. van den Broek, and P. H. Nibbering The Synthetic N-Terminal Peptide of Human Lactoferrin, hLF(1-11), Is Highly Effective against Experimental Infection Caused by Multidrug-Resistant Acinetobacter baumannii Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4919 - 4921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Grey, T. Banovic, Q. Zhu, M. Watson, K. Callon, K. Palmano, J. Ross, D. Naot, I. R. Reid, and J. Cornish The Low-Density Lipoprotein Receptor-Related Protein 1 Is a Mitogenic Receptor for Lactoferrin in Osteoblastic Cells Mol. Endocrinol., September 1, 2004; 18(9): 2268 - 2278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cornish, K. E. Callon, D. Naot, K. P. Palmano, T. Banovic, U. Bava, M. Watson, J.-M. Lin, P. C. Tong, Q. Chen, et al. Lactoferrin Is a Potent Regulator of Bone Cell Activity and Increases Bone Formation in Vivo Endocrinology, September 1, 2004; 145(9): 4366 - 4374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wen, C. P. Felley, H. Bouzourene, M. Reimers, P. Michetti, and Q. Pan-Hammarstrom Inflammatory Gene Profiles in Gastric Mucosa during Helicobacter pylori Infection in Humans J. Immunol., February 15, 2004; 172(4): 2595 - 2606. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
